These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18606526)

  • 1. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study.
    Arango C; Bobes J; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2008 Sep; 104(1-3):1-12. PubMed ID: 18606526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.
    Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2007 Feb; 90(1-3):162-73. PubMed ID: 17123783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study.
    Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Eur Psychiatry; 2012 May; 27(4):267-74. PubMed ID: 21036549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study.
    Arango C; Bobes J; Kirkpatrick B; Garcia-Garcia M; Rejas J
    Eur Neuropsychopharmacol; 2011 Dec; 21(12):867-75. PubMed ID: 21477998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vigilance level for cardiovascular risk factors in schizophrenic patients].
    Rouillon F; Van Ganse E; Vekhoff P; Arnaud R; Depret-Bixio L; Dillenschneider A
    Encephale; 2015 Feb; 41(1):70-7. PubMed ID: 25637197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of metabolic syndrome among inpatients with schizophrenia.
    Boke O; Aker S; Sarisoy G; Saricicek EB; Sahin AR
    Int J Psychiatry Med; 2008; 38(1):103-12. PubMed ID: 18624022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review.
    Wysokiński A; Kowman M; Kłoszewska I
    Psychiatr Danub; 2012 Sep; 24(3):314-22. PubMed ID: 23013638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
    Meyer JM; Nasrallah HA; McEvoy JP; Goff DC; Davis SM; Chakos M; Patel JK; Keefe RS; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):9-18. PubMed ID: 16125372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database.
    Sicras A; Rejas J; Navarro R; Serrat J; Blanca M
    Bipolar Disord; 2008 Jul; 10(5):607-16. PubMed ID: 18657245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study.
    Rejas J; Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M
    Schizophr Res; 2008 Feb; 99(1-3):23-8. PubMed ID: 18063343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
    Kagal UA; Torgal SS; Patil NM; Malleshappa A
    J Pharm Pract; 2012 Jun; 25(3):368-73. PubMed ID: 22551560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J
    Schizophr Res; 2010 Jun; 119(1-3):101-9. PubMed ID: 20219322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The metabolic syndrome and its components in participants of EUFEST].
    Rabe-Jabłońska J; Pawełczyk T
    Psychiatr Pol; 2008; 42(1):73-85. PubMed ID: 18567405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database.
    Sicras-Mainar A; Blanca-Tamayo M; Rejas-Gutiérrez J; Navarro-Artieda R
    Eur Psychiatry; 2008 Mar; 23(2):100-8. PubMed ID: 17904825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
    Schneiderhan ME; Batscha CL; Rosen C
    Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.
    Cerit C; Vural M; Bos Gelmez SÜ; Ozten E; Aker AT; Yıldız M
    Psychopharmacol Bull; 2010; 43(4):22-36. PubMed ID: 21240150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.